
The new technology enables a simple way of connecting the cytsteine residues (SH) of a tumor-sensing antibody (yellow) to toxic drug molecules. The emerging linker is highly stable during blood circulation and enables therefore a safe transport to the tumor side. (picture by Barth van Rossum/FMP)
Treating cancer more selectively and more effectively – this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU). The process transforms proteins and antibodies into stable, highly functional drug transporters, with which tumor cells can be detected and killed.
Classic chemotherapy for the treatment of cancer is based on toxic substances that are particularly effective for rapidly dividing cells. However, since healthy tissue also depends on cell division, treatment with chemotherapeutic substances is often accompanied by severe side effects. A dose sufficient to completely remove the tumor, would in many cases be too toxic to administer to a diseased person. With more modern approaches, it is now possible to transport active agents (drugs) in the body selectively to the site of action, for example by linking a drug with an antibody that can differentiate cancer cells from healthy tissue through changes on the surface of the cell. Five such Antibody Drug Conjugates (ADCs) are already on the market.
However, these ADCs lose a large part of their “toxic cargo” en route to the cancer cell. The substances (drugs) are released into the bloodstream and dangerous side effects can occur. A stable link between drug and antibody would therefore be highly desirable. This is precisely what the researchers – a team led by Professor Christian Hackenberger from the FMP and Professor Heinrich Leonhardt from the LMU Biocenter – focused on. Their results have been published in the prestigious journal, Angewandte Chemie: In two consecutive articles, the development of methods and the application of these methods to selective drug transport are presented.
The new drug transporters enable lower doses and less severe side effects
“We have developed an innovative technology that makes it possible to link native proteins and antibodies to complex molecules, such as fluorescent dyes or drugs more easily and with better stability than ever before,” reports Marc-André Kasper, a researcher in Christian Hackenberger’s group. The researchers discovered the outstanding properties of unsaturated phosphorus (V) compounds and took advantage of those. These phosphonamidates connect a desired modification – for example, a cancer-fighting agent – exclusively to the amino acid cysteine, in a protein or antibody. Since cysteine is a very rare natural occurring amino acid, the number of modifications per protein can be controlled quite effectively, which is essential for the construction of drug conjugates. In addition, phosphonamidates can easily be incorporated into complex chemical compounds. “The greatest achievement of the new method, however, is that the resulting bond is also stable during blood circulation,” says Marc-André Kasper. The ADCs that are on the market cannot achieve this.
To test the applicability on targeted drug delivery, the researchers compared their technology directly with the FDA-approved ADC, Adcetris®. The medication was re-created as precisely as possible with the same antibody and active agent, the only difference was that the innovative phosphonamidate linkage was used. When applied to blood serum, the researchers observed that their modified ADC lost significantly less active ingredient over a period of days. They also used the new technology in experiments with mice to combat Hodgkin’s lymphoma. The preparation proved to be more effective than the conventional medication. “From our results, we conclude that phosphonamidate-linked drug transporters can be administered in lower doses, and that side effects can be further reduced. Thus the technology has great potential to replace current methods in order to develop more effective and safer ADCs in the future,” says FMP group leader Christian Hackenberger.
In the next step, the research groups will continue their efforts in the development of ADCs based on phosphonamidates. Preclinical studies, which are essential for the treatment of patients, are already underway. In this regard, the promising start-up company Tubulis, which was awarded the Leibniz Start-Up Prize last year, functions as a platform for the further development to market maturity.
Learn more: Bringing cancer medication safely to its destination
The Latest on: Antibody Drug Conjugates
[google_news title=”” keyword=”Antibody Drug Conjugates” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Antibody Drug Conjugates
- Lotte Biologics looks to establish itself as key CDMO player globallyon February 9, 2023 at 2:20 am
The South Korean player plans to expand its recently acquired US facility, provide contract manufacturing services for Antibody Drug Conjugates (ADC), and to add drug product fill & finish facilities ...
- Antibody Drug Conjugates Global Market Report 2023on February 8, 2023 at 9:10 am
Major players in the antibody-drug conjugates (ADCs) market are Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., Immunomedics Inc., Oxford BioTherapeutics, Pfizer Inc., Seattle Genetics ...
- Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Boardon February 8, 2023 at 5:00 am
Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that discovers novel target-antibody pairs through its unbiased interrogation of the human immune response, today announced ...
- Cancer Antibody Drug Conjugates Market Production Growth, Demand And Supply Analysis 2023 To 2028 | Including 108 Pages Reporton February 7, 2023 at 6:18 pm
Cancer Antibody Drug Conjugates Market [108 Report Pages and 148 Number of Tables and Figures ] Insights 2023 by ...
- Antibody-drug Conjugates Market Size Analysis between Top International Players through Business Aspects way 2025on February 6, 2023 at 5:44 am
The Global Antibody-drug Conjugates market is valued at million USD in 2018 and will reach million USD by the end of 2025, growing at a CAGR of percent during 2019-2025. The objectives of this study ...
- Bardia Explores Outcomes for Antibody-Drug Conjugates in TNBCon February 6, 2023 at 3:00 am
During a Targeted Oncology case-based roundtable event, Aditya Bardia, MD, MPH, discussed the data supporting the use of sacituzumab govitecan in patients with triple-negative breast cancer.
- Antibody Drug Conjugates Contract Market Size to Hit US$ 38.8 Billion by 2032, Growing at a CAGR of 15.5%: Fact.MRon January 31, 2023 at 7:10 am
Rockville, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Fact.MR – A Market Research and Competitive Intelligence Provider: The Antibody Drug Conjugates Contract industry revenues were valued at US$ 8.1Bn ...
- Antibody Drug Conjugates Contract Market Size to Hit US$ 38.8 Billion by 2032, Growing at a CAGR of 15.5%: Fact.MRon January 30, 2023 at 10:10 am
Antibody Drug Conjugates Contract market is expected to cross the market value of US$ 9.2 Bn by 2022. The Asia Pacific is anticipated to be the most lucrative region in terms of growth.
- Antibody-drug Conjugates: Technology Growth Opportunitieson January 28, 2023 at 6:43 pm
New York, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Antibody-drug Conjugates: Technology Growth Opportunities" - https ...
- Antibody-drug Conjugates Growth Opportunities 2022: Disruptive Technologies and a Conducive Funding Environment are Fostering Growthon January 26, 2023 at 12:57 pm
DUBLIN, Jan. 26, 2023 /PRNewswire/ -- The "Antibody-drug Conjugates: Technology Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. Antibody-drug conjugates (ADCs) are ...
via Bing News